Parathyroid hormone(1-84) treatment of postmenopausal women with low bone mass receiving hormone replacement therapy.

Fogelman I, Fordham JN, Fraser WD, Spector TD, Christiansen C, Morris SA, Fox J

Calcified tissue international15 Jul 2008Cited by 12 (Europe PMC)

PMID18626566DOI10.1007/s00223-008-9152-3PepBankPUB-18626566

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study12

12 results from studies that gave the peptide. 12 results from people.

01HumanRandomized controlled trialEfficacy outcome
In postmenopausal women receiving HT, lumbar spine BMD increased 7.9% with PTH(1-84) versus 1.5% with HT alone at 18 months.
In plain wordsIn postmenopausal women receiving HT, spine bone density increased 7.9% with PTH versus 1.5% with HT alone at 18 months.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
IncreaseLumbar spine BMD at 18 months
Study
n: not reported in source
Comparator
HT alone
Analysis
Primary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
100 microg daily · injectionAs given in this study (human).
Measurements
Mean lumbar spine BMD increase at 18 months
7.9%
PTH(1-84) plus HT
Mean lumbar spine BMD increase at 18 months
1.5%
HT alone
Source sentences
Summary
At 18 months, the mean increase in lumbar spine BMD was 7.9% for PTH(1-84) subjects vs. 1.5% for those receiving HT alone; between-group differences were significant at 6 months and persisted throughout the study.
3 context sentences(design, population, supporting numbers)
Summary · context
The primary efficacy outcome was change from baseline in lumbar spine BMD.
Summary · context
To evaluate whether anabolic therapy together with HT provides additional benefits in the treatment of PMO, we evaluated the effects of parathyroid hormone (PTH) 1-84 in postmenopausal women with low bone mineral density (BMD) who were receiving chronic (> or =6 months) HT. Subjects were randomized…
Summary · context
The study was terminated early following recommendations regarding HT for PMO.
Report a problemFND-1862656601
02HumanRandomized controlled trialEfficacy outcome
In postmenopausal women receiving HT, PTH(1-84) increased lumbar spine BMD versus HT alone significantly at 6 months and thereafter.
In plain wordsIn postmenopausal women receiving HT, PTH increased spine bone density versus HT alone at 6 months and thereafter.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
IncreaseLumbar spine BMD between-group difference at 6 months
Study
n: not reported in source
Comparator
HT alone
Analysis
Primary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
100 microg daily · injectionAs given in this study (human).
Source sentences
Summary
At 18 months, the mean increase in lumbar spine BMD was 7.9% for PTH(1-84) subjects vs. 1.5% for those receiving HT alone; between-group differences were significant at 6 months and persisted throughout the study.
3 context sentences(design, population, supporting numbers)
Summary · context
The primary efficacy outcome was change from baseline in lumbar spine BMD.
Summary · context
To evaluate whether anabolic therapy together with HT provides additional benefits in the treatment of PMO, we evaluated the effects of parathyroid hormone (PTH) 1-84 in postmenopausal women with low bone mineral density (BMD) who were receiving chronic (> or =6 months) HT. Subjects were randomized…
Summary · context
The study was terminated early following recommendations regarding HT for PMO.
Report a problemFND-1862656602
03HumanRandomized controlled trialEfficacy outcome
In postmenopausal women receiving HT, femoral neck BMD was significantly higher with PTH(1-84) than HT alone.
In plain wordsIn postmenopausal women receiving HT, femoral neck bone density was higher with PTH than HT alone.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
IncreaseFemoral neck BMD
Study
n: not reported in source
Comparator
HT alone
Analysis
Secondary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
100 microg daily · injectionAs given in this study (human).
Source sentences
Summary
Femoral neck BMD and bone turnover markers were significantly higher in PTH(1-84)-treated subjects, but the changes in total hip and distal radius BMD were not significant.
3 context sentences(design, population, supporting numbers)
Summary · context
Secondary end points included changes in hip and distal radius BMD, bone turnover markers, and fracture incidence.
Summary · context
To evaluate whether anabolic therapy together with HT provides additional benefits in the treatment of PMO, we evaluated the effects of parathyroid hormone (PTH) 1-84 in postmenopausal women with low bone mineral density (BMD) who were receiving chronic (> or =6 months) HT. Subjects were randomized…
Summary · context
The study was terminated early following recommendations regarding HT for PMO.
Report a problemFND-1862656604
04HumanRandomized controlled trialEfficacy outcome
In postmenopausal women receiving HT, bone turnover markers were significantly higher with PTH(1-84) than HT alone.
In plain wordsIn postmenopausal women receiving HT, bone turnover markers were higher with PTH than HT alone.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
IncreaseBone turnover markers
Study
n: not reported in source
Comparator
HT alone
Analysis
Secondary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
100 microg daily · injectionAs given in this study (human).
Source sentences
Summary
Femoral neck BMD and bone turnover markers were significantly higher in PTH(1-84)-treated subjects, but the changes in total hip and distal radius BMD were not significant.
3 context sentences(design, population, supporting numbers)
Summary · context
Secondary end points included changes in hip and distal radius BMD, bone turnover markers, and fracture incidence.
Summary · context
To evaluate whether anabolic therapy together with HT provides additional benefits in the treatment of PMO, we evaluated the effects of parathyroid hormone (PTH) 1-84 in postmenopausal women with low bone mineral density (BMD) who were receiving chronic (> or =6 months) HT. Subjects were randomized…
Summary · context
The study was terminated early following recommendations regarding HT for PMO.
Report a problemFND-1862656605
05HumanRandomized controlled trialEfficacy outcome
In postmenopausal women receiving HT, total hip BMD changes with PTH(1-84) were not significant.
In plain wordsIn postmenopausal women receiving HT, PTH did not significantly change total hip bone density compared with HT alone.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
No significant changeTotal hip BMD
Study
n: not reported in source
Comparator
HT alone
Analysis
Secondary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
100 microg daily · injectionAs given in this study (human).
Source sentences
Summary
Femoral neck BMD and bone turnover markers were significantly higher in PTH(1-84)-treated subjects, but the changes in total hip and distal radius BMD were not significant.
3 context sentences(design, population, supporting numbers)
Summary · context
Secondary end points included changes in hip and distal radius BMD, bone turnover markers, and fracture incidence.
Summary · context
To evaluate whether anabolic therapy together with HT provides additional benefits in the treatment of PMO, we evaluated the effects of parathyroid hormone (PTH) 1-84 in postmenopausal women with low bone mineral density (BMD) who were receiving chronic (> or =6 months) HT. Subjects were randomized…
Summary · context
The study was terminated early following recommendations regarding HT for PMO.
Report a problemFND-1862656606
06HumanRandomized controlled trialEfficacy outcome
In postmenopausal women receiving HT, distal radius BMD changes with PTH(1-84) were not significant.
In plain wordsIn postmenopausal women receiving HT, PTH did not significantly change wrist bone density compared with HT alone.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
No significant changeDistal radius BMD
Study
n: not reported in source
Comparator
HT alone
Analysis
Secondary
Outcome group
Bone and joint · Musculoskeletal
Studied dose
100 microg daily · injectionAs given in this study (human).
Source sentences
Summary
Femoral neck BMD and bone turnover markers were significantly higher in PTH(1-84)-treated subjects, but the changes in total hip and distal radius BMD were not significant.
3 context sentences(design, population, supporting numbers)
Summary · context
Secondary end points included changes in hip and distal radius BMD, bone turnover markers, and fracture incidence.
Summary · context
To evaluate whether anabolic therapy together with HT provides additional benefits in the treatment of PMO, we evaluated the effects of parathyroid hormone (PTH) 1-84 in postmenopausal women with low bone mineral density (BMD) who were receiving chronic (> or =6 months) HT. Subjects were randomized…
Summary · context
The study was terminated early following recommendations regarding HT for PMO.
Report a problemFND-1862656607
07HumanRandomized controlled trialEfficacy outcome
In postmenopausal women, lumbar spine BMD increased in 94% receiving PTH(1-84) with HT versus 59% receiving HT alone.
In plain wordsIn postmenopausal women, spine bone density increased in 94% with PTH and HT versus 59% with HT alone.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
IncreaseProportion with lumbar spine BMD increase
Study
n: not reported in source
Comparator
HT alone
Outcome group
Bone and joint · Musculoskeletal
Studied dose
100 microg daily · injectionAs given in this study (human).
Measurements
Women with lumbar spine BMD increase
94%
PTH(1-84) plus HT
Women with lumbar spine BMD increase
59%
HT alone
Source sentences
Summary
Lumbar spine BMD increased in 94% of women receiving PTH(1-84) compared to 59% for HT alone.
2 context sentences(design, population, supporting numbers)
Summary · context
To evaluate whether anabolic therapy together with HT provides additional benefits in the treatment of PMO, we evaluated the effects of parathyroid hormone (PTH) 1-84 in postmenopausal women with low bone mineral density (BMD) who were receiving chronic (> or =6 months) HT. Subjects were randomized…
Summary · context
The study was terminated early following recommendations regarding HT for PMO.
Report a problemFND-1862656603
08HumanRandomized controlled trialSafety outcome
In postmenopausal women, hypercalciuria occurred more frequently with HT plus PTH(1-84) than HT alone.
In plain wordsIn postmenopausal women, high urinary calcium occurred more often with PTH and HT than HT alone.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
IncreaseHypercalciuria
Study
n: not reported in source
Comparator
HT alone
Outcome group
Adverse events · Kidney and urinary
Studied dose
100 microg daily · injectionAs given in this study (human).
Source sentences
Summary
PTH(1-84) treatment was generally well-tolerated, with hypercalciuria, hypercalcemia, nausea, vomiting, and dizziness reported more frequently in the HT + PTH(1-84) group.
2 context sentences(design, population, supporting numbers)
Summary · context
To evaluate whether anabolic therapy together with HT provides additional benefits in the treatment of PMO, we evaluated the effects of parathyroid hormone (PTH) 1-84 in postmenopausal women with low bone mineral density (BMD) who were receiving chronic (> or =6 months) HT. Subjects were randomized…
Summary · context
The study was terminated early following recommendations regarding HT for PMO.
Report a problemFND-1862656608
09HumanRandomized controlled trialSafety outcome
In postmenopausal women, hypercalcemia occurred more frequently with HT plus PTH(1-84) than HT alone.
In plain wordsIn postmenopausal women, high blood calcium occurred more often with PTH and HT than HT alone.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
IncreaseHypercalcemia
Study
n: not reported in source
Comparator
HT alone
Outcome group
Adverse events · Endocrine and hormones
Studied dose
100 microg daily · injectionAs given in this study (human).
Source sentences
Summary
PTH(1-84) treatment was generally well-tolerated, with hypercalciuria, hypercalcemia, nausea, vomiting, and dizziness reported more frequently in the HT + PTH(1-84) group.
2 context sentences(design, population, supporting numbers)
Summary · context
To evaluate whether anabolic therapy together with HT provides additional benefits in the treatment of PMO, we evaluated the effects of parathyroid hormone (PTH) 1-84 in postmenopausal women with low bone mineral density (BMD) who were receiving chronic (> or =6 months) HT. Subjects were randomized…
Summary · context
The study was terminated early following recommendations regarding HT for PMO.
Report a problemFND-1862656609
10HumanRandomized controlled trialSafety outcome
In postmenopausal women, nausea occurred more frequently with HT plus PTH(1-84) than HT alone.
In plain wordsIn postmenopausal women, nausea occurred more often with PTH and HT than HT alone.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
IncreaseNausea
Study
n: not reported in source
Comparator
HT alone
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
100 microg daily · injectionAs given in this study (human).
Source sentences
Summary
PTH(1-84) treatment was generally well-tolerated, with hypercalciuria, hypercalcemia, nausea, vomiting, and dizziness reported more frequently in the HT + PTH(1-84) group.
2 context sentences(design, population, supporting numbers)
Summary · context
To evaluate whether anabolic therapy together with HT provides additional benefits in the treatment of PMO, we evaluated the effects of parathyroid hormone (PTH) 1-84 in postmenopausal women with low bone mineral density (BMD) who were receiving chronic (> or =6 months) HT. Subjects were randomized…
Summary · context
The study was terminated early following recommendations regarding HT for PMO.
Report a problemFND-1862656610
11HumanRandomized controlled trialSafety outcome
In postmenopausal women, vomiting occurred more frequently with HT plus PTH(1-84) than HT alone.
In plain wordsIn postmenopausal women, vomiting occurred more often with PTH and HT than HT alone.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
IncreaseVomiting
Study
n: not reported in source
Comparator
HT alone
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
100 microg daily · injectionAs given in this study (human).
Source sentences
Summary
PTH(1-84) treatment was generally well-tolerated, with hypercalciuria, hypercalcemia, nausea, vomiting, and dizziness reported more frequently in the HT + PTH(1-84) group.
2 context sentences(design, population, supporting numbers)
Summary · context
To evaluate whether anabolic therapy together with HT provides additional benefits in the treatment of PMO, we evaluated the effects of parathyroid hormone (PTH) 1-84 in postmenopausal women with low bone mineral density (BMD) who were receiving chronic (> or =6 months) HT. Subjects were randomized…
Summary · context
The study was terminated early following recommendations regarding HT for PMO.
Report a problemFND-1862656611
12HumanRandomized controlled trialSafety outcome
In postmenopausal women, dizziness occurred more frequently with HT plus PTH(1-84) than HT alone.
In plain wordsIn postmenopausal women, dizziness occurred more often with PTH and HT than HT alone.
Peptide
PTH 1-84 (parathyroid hormone)
Outcome
IncreaseDizziness
Study
n: not reported in source
Comparator
HT alone
Outcome group
Adverse events · Nervous system and cognition
Studied dose
100 microg daily · injectionAs given in this study (human).
Source sentences
Summary
PTH(1-84) treatment was generally well-tolerated, with hypercalciuria, hypercalcemia, nausea, vomiting, and dizziness reported more frequently in the HT + PTH(1-84) group.
2 context sentences(design, population, supporting numbers)
Summary · context
To evaluate whether anabolic therapy together with HT provides additional benefits in the treatment of PMO, we evaluated the effects of parathyroid hormone (PTH) 1-84 in postmenopausal women with low bone mineral density (BMD) who were receiving chronic (> or =6 months) HT. Subjects were randomized…
Summary · context
The study was terminated early following recommendations regarding HT for PMO.
Report a problemFND-1862656612

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:37 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.